Rongtai health(SH:603579) Guotou Securities·2025-11-03 09:19Investment Rating - The investment rating for the company is "Buy-A" with a target price of 37.05 CNY for the next 6 months [6]. Core Views - The company has shown signs of recovery in domestic sales due to the old-for-new subsidy policy, while its export sales faced pressure from tariff policies. The expansion into automotive massage seats and rehabilitation robots is expected to drive future growth [2][3][5]. Financial Performance Summary - For the first three quarters of 2025, the company achieved a revenue of 1.15 billion CNY, a year-over-year decrease of 1.4%, and a net profit attributable to shareholders of 110 million CNY, down 22.2% year-over-year. In Q3 alone, revenue was 340 million CNY, a slight decline of 0.4% year-over-year, with a net profit of 30 million CNY, down 18.3% year-over-year [2][4]. - The gross margin for Q3 improved to 31.1%, an increase of 0.7 percentage points year-over-year, attributed to a higher proportion of domestic business. However, the net profit margin decreased to 7.5%, down 1.6 percentage points year-over-year due to increased operating expenses [4]. - The company reported a slight net outflow of operating cash flow in Q3, amounting to -20 million CNY, compared to a positive cash flow of 30 million CNY in the same period last year [4]. Business Development Summary - The domestic sales have shown a significant recovery, with online sales for the company's brands increasing by 82.0% year-over-year in Q3. The company is also focusing on expanding its overseas market, which is expected to rebound [3][5]. - The introduction of the 4D mechanical massage seat in the new Zhiji LS9 model is a notable development, indicating the company's commitment to innovation in the automotive sector [3]. - The company is actively investing in research and development for its automotive massage seat and rehabilitation robot businesses, which are anticipated to create new growth trajectories [5].